Fairvalue-Calculator Fairvalue-Calculator
EN DE

Satellos Bioscience Inc (MSLE) Fair Value & Analysis

Healthcare · US · Market cap $119M

Price$5.67
Fair Value$4.00
Upside-29.5%
Quality95/100
Evidence: Low Range $3.00 – $5.00

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Satellos Bioscience Inc (MSLE) currently trades at $5.67, while our model-based Fair Value estimate is $4.00 — implying the stock looks roughly 29.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Satellos Bioscience Inc (MSLE) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $4.00 versus a price of $5.67 — about −29% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MSLE?
Our 21-model fair value for Satellos Bioscience Inc is $4.00 (as of Jun 24, 2026), built from audited fundamentals. The current price is $5.67.
What is the quality score of MSLE?
Satellos Bioscience Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.